Crossing the Cholesterol Finishing Line

Treating to tight targets to save lives

FREE EDUCATION

Now available on-demand for Praxhub members

About this education

Despite the robustness of the literature on the topic, Australian clinicians and their patients still have a long way to go in optimising the management of dyslipidaemia. 50% of Australians have a total cholesterol above 5 mmol/l [1] and 57.5% of Australians in the high cardiovascular risk category are not appropriately treated for their risk factors [2].


This education explores the state of dyslipidaemia management in Australia via a panel-based discussion. It covers the prevalence, causes and impacts of poor lipid control, and explores the barriers to optimal lipid-lowering. The myriad treatment options are discussed, suggesting a rational and structured approach to lipid-lowering, including the role of PCSK9 inhibitors and emerging medication options.

Panellists also discuss the conundrum of the lack of definitive Australian lipid-lowering guidelines, and how cardiologists and GPs can collaborate on assertive cholesterol-lowering to the benefit of their patients.
quote-leftFont Awesome Free 5.0.6 by @fontawesome - http://fontawesome.com License - http://fontawesome.com/license (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License)

This was an excellent outline of dyslipidaemia management by both presenters. The best on the subject that I have been to in the last 2 years. Clear, concise and useful.

Live webinar attendee
MBBS(Hons) FRACGP MPH
GradCertClinTeach
General Practitioner & Medical Educator

Dr Anita Muñoz

MBBS FRACP FCSANZ
Cardiologist, Barwon Health


MMBS PhD FRACP FACC FESC FAHA
FCSANZ FAHNMS
Director of MonashHeart
Director of Victorian Heart Institute
Professor of Cardiology, Monash University

Your Presenters

By the end of this activity, you will be able to:

3

Outline the barriers to definitive lipid-lowering, ways of troubleshooting those, and methods for collaboration with general practitioners


2

List the current treatment options for cholesterol lowering and a framework for rational and targetinformed prescribing


1

Describe the current state of dyslipidaemia in Australia, including prevalence, causes and impacts on health outcomes


Learning Outcomes

2. Hespe, C .M., Giskes, K ., Harris, M.F. et al . Findings and lessons learnt implementing a cardiovascular disease qualit y improvement program in Australian primary care: a mixed method evaluation. BMC Health Serv Res 22, 108 (2022). https://doi .org/10.1186/s12913-021 -07310-6


The sponsor has provided no input in the content of this education